T0	KEYPHRASE-NOTYPES 5 13	patients
T1	KEYPHRASE-NOTYPES 32 37	study
T2	KEYPHRASE-NOTYPES 49 63	adverse events
T3	KEYPHRASE-NOTYPES 80 88	thrombus
T4	KEYPHRASE-NOTYPES 98 102	drug
T5	KEYPHRASE-NOTYPES 120 144	staphylococcal infection
T6	KEYPHRASE-NOTYPES 149 156	placebo
T7	KEYPHRASE-NOTYPES 178 195	allergic reaction
T8	KEYPHRASE-NOTYPES 200 204	drug
T9	KEYPHRASE-NOTYPES 236 246	joint pain
T10	KEYPHRASE-NOTYPES 251 258	placebo
T11	KEYPHRASE-NOTYPES 274 298	narcotic pain medication
T12	KEYPHRASE-NOTYPES 305 313	patients
T13	KEYPHRASE-NOTYPES 330 335	study
T14	KEYPHRASE-NOTYPES 344 358	adverse events
T15	KEYPHRASE-NOTYPES 380 397	early termination
T16	KEYPHRASE-NOTYPES 401 417	study medication
T17	KEYPHRASE-NOTYPES 428 432	drug
T18	KEYPHRASE-NOTYPES 443 461	allergic reactions
T19	KEYPHRASE-NOTYPES 476 490	abdominal pain
T20	KEYPHRASE-NOTYPES 495 510	hospitalization
T21	KEYPHRASE-NOTYPES 519 523	drug
T22	KEYPHRASE-NOTYPES 525 540	cholecystectomy
T23	KEYPHRASE-NOTYPES 544 548	week
T24	KEYPHRASE-NOTYPES 564 572	patients
T25	KEYPHRASE-NOTYPES 574 581	ratings
T26	KEYPHRASE-NOTYPES 585 590	weeks
T27	KEYPHRASE-NOTYPES 645 668	treatment randomization
T28	KEYPHRASE-NOTYPES 674 691	adverse reactions
T29	KEYPHRASE-NOTYPES 715 723	patients
T30	KEYPHRASE-NOTYPES 781 796	study treatment
T31	KEYPHRASE-NOTYPES 798 806	presence
T32	KEYPHRASE-NOTYPES 812 821	PICC line
T33	KEYPHRASE-NOTYPES 825 835	medication
T34	KEYPHRASE-NOTYPES 844 848	rate
T35	KEYPHRASE-NOTYPES 852 884	treatment-related adverse events
T36	KEYPHRASE-NOTYPES 910 918	patients
T37	KEYPHRASE-NOTYPES 928 939	ceftriaxone
T38	KEYPHRASE-NOTYPES 965 973	patients
T39	KEYPHRASE-NOTYPES 983 990	placebo
T40	KEYPHRASE-NOTYPES 996 1004	patients
